95470-42-1

Basic information

• Product Name: IFLAB-BB F2108-0155
• Synonyms: IFLAB-BB F2108-0155;2-BROMO-5-METHYL-3H-IMIDAZOLE-4-CARBOXYLIC ACID ETHYL ESTER;2-BROMO-5-METHYL-1H-IMIDAZOLE-4-CARBOXYLIC ACID ETHYL ESTER;2-Bromo-5-methyl-4H-imidazole-4-carboxylic acid ethyl ester;ethyl 2-broMo-5-Methyl-1H-iMidazole-4-carboxylate;Ethyl 2-broMo-5-Methyl-4H-iMidazole-4-carboxylate;Ethyl 2-bromo-4-methyl-1H-imidazole-5-carboxylate;1H-Imidazole-5-carboxylic acid,2-bromo-4-methyl-,ethyl ester
• CAS NO: 95470-42-1
• Molecular Formula: C₇H₉BrN₂O₂
• Molecular Weight: 233.07
• Mol File: 95470-42-1.mol

Chemical Properties

• Melting Point: 152-153 °C
• Boiling Point: 265.275 °C at 760 mmHg
• Flash Point: 114.235 °C
• Appearance: /
• Density: 1.656 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 8.81±0.10(Predicted)
• CAS DataBase Reference: IFLAB-BB F2108-0155(CAS DataBase Reference)
• NIST Chemistry Reference: IFLAB-BB F2108-0155(95470-42-1)
• EPA Substance Registry System: IFLAB-BB F2108-0155(95470-42-1)

Safety Data

• Hazardous Substances Data: 95470-42-1(Hazardous Substances Data)

Usage

Uses

Used in Fragrance and Flavoring Industry:
IFLAB-BB F2108-0155 is used as a key ingredient for its strong, pungent odor, contributing to the creation of various fragrances and flavorings in products such as perfumes, soaps, and other scented items.
Used in Organic Synthesis:
IFLAB-BB F2108-0155 is used as a starting material in the synthesis of a wide range of organic compounds, playing a crucial role in the development of new chemical entities.
Used in Pharmaceutical Industry:
IFLAB-BB F2108-0155 is used as a pharmaceutical intermediate, aiding in the production of various medications by serving as a precursor in their chemical synthesis processes.
Used in Scientific Research and Analytical Chemistry:
IFLAB-BB F2108-0155 is used as a reagent in scientific research and analytical chemistry due to its reactivity with multiple compounds, which facilitates the identification and quantification of specific chemical substances.

Upstream product

• 51605-32-4 Ethyl 5-Methyl-4-imidazolecarboxylate 
• 51605-32-4 ethyl 4⁽⁵⁾-methylimidazole-5⁽⁴⁾-carboxylate 

Downstream Products

• 113444-43-2 ethyl 2-bromo-1,4-dimethyl-1H-imidazole-5-carboxylate 
• 139261-80-6 ethyl 2-p-chlorophenylamino-4⁽⁵⁾-methyl-5⁽⁴⁾-imidazole carboxylate hydrochloride 
• 139261-79-3 ethyl 2-(N-piperidino)-4(5)-methyl-5(4)-imidazole carboxylate hydrochloride 
• 1144520-06-8 (2-phenyl-4-methyl-1H-imidazol-5-ylcarbonyl)guanidine 

Relevant articles and documents

PYRAZINE DERIVATIVE

Provided is a novel pyrazine derivative represented by the following formula (I) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which URAT1 is involved, including gout, hyperurice

HETEROARYL INHIBITORS OF PAD4

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

NOVEL CRYSTALLINE POLYMORPHS OF PYRIDINE DERIVATIVE AND METHOD FOR PRODUCING THE SAME

Disclosed are crystals of 2-(5-chloropyridin-3-yl)-1-(2,5-dichlorobenzyl)-4-methyl-1H-imidazole-5-carboxylic acid useful as therapeutic or prophylactic agents for gout, hyperuricemia, and the like, and a method for producing the crystals.

PYRIDINE DERIVATIVE

Provided is a pyridine derivative represented by formula (I), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, wh

IMIDAZOLE DERIVATIVE

PROBLEM TO BE SOLVED: To provide a novel pyrazine derivative that is useful as a therapeutic agent or preventive agent for diseases associated with URAT1, such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes,

Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3- ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists

A novel series of [6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a] imidazol-3-ylmethyl]-dialkylamines was discovered as potent CRF1R antagonists. The optimization of binding affinity in the series by the parallel reaction approach is discus

(2-Aryl-5-methylimidazol-4-ylcarbonyl)guanidines and (2-aryl-5-methyloxazol-4-ylcarbonyl)guanidines as NHE-1 inhibitors

A series of (2-aryl-5-methylimidazol-4-ylcarbonyl)guanidines and (2-aryl-5-methyloxazol-4-ylcarbonyl)guanidines were synthesized and evaluated as NHE-1 inhibitors. The structure-activity relationships well matched those of furan derivatives, which were previously investigated. The (2,5-disubstituted)phenyl compounds showed better activities than the other analogues in both imidazole and oxazole compounds. Especially, 2-(2,5-dichlorophenyl)imidazole 52, and 2-(2-methoxy-5-chlorophenyl)imidazole 54 compounds exhibited potent cardioprotective efficacy both in vitro and in vivo as well as high NHE-1 inhibitory activities.

ORGANIC COMPOUNDS

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

4-METHYLIMIDAZOL-5-YLCARBONYLGUANIDINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF THE ISCHEMIC HEART DISEASES CONTAINING THE SAME AS AN ACTIVE INGREDIENT

Disclosed are novel 4-methylimidazol-5- ylcarbonylguanidine derivatives, pharmaceutically acceptable salts thereof, preparation methods thereof, and pharmaceutical composition for the prevention and treatment of ischemic heart diseases, comprising the same as an active ingredient. Having potent inhibitory activity against NHE-I and excellent protective effects on the heart against ischemia/reperfusion, the novel 4-methylimidazol-5- ylcarbonylguanidine derivatives can be used for the prophylaxis and treatment of ischemic cardiac diseases such as myocardiac infarction, arrhythmia, and angina pectoris and can serve as a cardioprotective agent applicable for coronary reperfusion therapy with coronary artery bypass, percutaneous transluminal coronary angioplasty, and/or thrombolytics for myocardiac infarction.